Clinical trials for prostate cancer

50 currently recruiting clinical trials
Prostate cancer

Phase 3 Prostate cancer
#NCT05348577
Adenocarcinoma Metastatic Castration-resistant Hormone therapy
Targeted therapy
Hôpital Pellegrin (Bordeaux), Centre Hospitalier Régional Et Universitaire CHRU de Brest (Brest), Centre Hospitalier Universitaire de Clermont Ferrand (Clermont-Ferrand), Centre Hospitalier Intercommunal Créteil (Créteil Cedex), Hôpital de la Timone AP-HM (Marseille) (and 9 more...)
AstraZeneca
Phase 3 Prostate cancer
#NCT05884398
Adenocarcinoma Metastatic Hormone-sensitive Hormone therapy
Centre Léon Bérard (Lyon), CHU de Rennes - Hôpital Pontchaillou (Rennes), Gustave Roussy (Villejuif), Institut Bergonié (Bordeaux), Hôpital Cochin (Paris )
Janssen
Phase 3 Prostate cancer
#NCT04115007
Adenocarcinoma Metastatic Hormone-sensitive
Institut Sainte Catherine (Avignon), Institut Bergonié (Bordeaux), CHP Brest - Pasteur Vivalto Santé (Brest), Centre Hospitalier Régional Et Universitaire CHRU de Brest (Brest), Centre François Baclesse (Caen ) (and 26 more...)
UNICANCER
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer
#NCT03767075
Locally Advanced Metastatic Metastatic Castration-resistant
Systemic Treatment-Naive
Gustave Roussy (Villejuif)
Institut d'oncologie du Vall d'Hebron
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Pancreas cancer
#NCT04924075
Locally Advanced Metastatic Other mutation
Systemic Treatment-Naive
Institut Paoli-Calmettes (Marseille), Hôpital Bicêtre AP-HP (Le Kremlin-Bicêtre), Hôpital Cochin (Paris ), Hôpital Edouard Herriot - Hospices Civils de Lyon (Lyon), Hôpital de Hautepierre - Hôpitaux Universitaires de Strasbourg (Strasbourg) (and 1 more...)
Merck Sharp & Dohme LLC
Phase 2 Breast cancer Lung cancer Prostate cancer Kidney cancer
#NCT04705818
Locally Advanced Metastatic Metastatic Castration-resistant
Immunotherapy Immunotherapy
Centre Hospitalier Universitaire de Poitiers - Site de la Milétrie (Poitiers), Centre Hospitalier Régional Et Universitaire CHRU de Brest (Brest), Institut Bergonié (Bordeaux)
Institut Bergonié
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer
#NCT04657068
Locally Advanced Metastatic Metastatic Castration-resistant ATM Other mutation
Systemic Treatment-Naive
Gustave Roussy (Villejuif)
Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Liver and bile duct cancer
#NCT05275478
Locally Advanced Metastatic Metastatic Castration-resistant Other mutation
Systemic Treatment-Naive Systemic Treatment-Naive
Institut Bergonié (Bordeaux), Centre Léon Bérard (Lyon), Institut de Cancérologie de l'Ouest - Site de Saint-Herblain (Saint-Herblain), Gustave Roussy (Villejuif)
Tango Therapeutics
Phase 2 Prostate cancer
#NCT06004661
Metastatic Castration-resistant Hormone therapy PSMA PET Positive
Systemic Treatment-Naive Internal Vectorised Radiotherapy (IVR)
CHRU de Nancy - Hôpitaux de Brabois (Vandœuvre-lès-Nancy), Hôpital Cochin (Paris )
Novartis
Phase 2 Prostate cancer
#NCT05849298
Metastatic Castration-resistant Immunotherapy Internal Vectorised Radiotherapy (IVR) PSMA PET Positive
Institut de Cancérologie de l'Ouest - Site d'Angers (Angers ), Hôpital Cochin (Paris ), ICANS - Institut de cancérologie Strasbourg Europe (Strasbourg), CHU Caen Normandie (Caen)
Novartis